Serina Therapeutics (NYSEAMERICAN:SER) Announces Quarterly Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) released its earnings results on Thursday. The company reported ($0.31) EPS for the quarter, FiscalAI reports. The company had revenue of $0.13 million during the quarter.

Serina Therapeutics Stock Down 6.0%

Shares of NYSEAMERICAN:SER traded down $0.09 during trading hours on Thursday, reaching $1.41. The stock had a trading volume of 28,387 shares, compared to its average volume of 1,352,017. Serina Therapeutics has a 1 year low of $1.14 and a 1 year high of $4.26. The firm’s 50 day moving average is $1.99 and its 200-day moving average is $2.05. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. The stock has a market capitalization of $35.81 million, a price-to-earnings ratio of -0.75 and a beta of 1.29.

Institutional Investors Weigh In On Serina Therapeutics

A hedge fund recently bought a new position in Serina Therapeutics stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Serina Therapeutics, Inc. (NYSEAMERICAN:SER) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 88,888 shares of the company’s stock, valued at approximately $178,000. Ashton Thomas Private Wealth LLC owned approximately 0.35% of Serina Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of Serina Therapeutics in a research note on Monday, October 26th. One analyst has rated the stock with a Buy rating. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.00.

About Serina Therapeutics

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability. Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.